
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$80.69
+US$1.05 · +1.32%
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
前收盘价
US$80.69
+US$1.05 · +1.32%
盘中时间采用ET。市场数据可能有所延迟。
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
日内区间
当前US$80.69
52周区间
当前US$80.69
盘中时间采用ET。市场数据可能有所延迟。
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
日内区间
当前US$80.69
52周区间
当前US$80.69
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.5亿 USD | 2.2亿 USD | 1.93亿 USD | 1.62亿 USD | 1.54亿 USD |
| 销货成本 | 7106.3万 USD | 6896.2万 USD | 6643.5万 USD | 5675.5万 USD | 5304.2万 USD |
| 毛利 | 1.79亿 USD | 1.51亿 USD | 1.27亿 USD | 1.05亿 USD | 1.01亿 USD |
| 研究与开发 | 1413.9万 USD | 1565万 USD | 1696.6万 USD | 1329.4万 USD | 1180.1万 USD |
| 销售、一般及管理费用 | 9648.8万 USD | 8299.5万 USD | 7288.6万 USD | 6166.6万 USD | 5315.6万 USD |
| 营业费用 | 1.11亿 USD | 9864.5万 USD | 9033.7万 USD | 7806.7万 USD | 6495.7万 USD |
| 利息收入 | 1309.4万 USD | 494.9万 USD | 307.7万 USD | 98.6万 USD | 19.7万 USD |
| 利息支出 | 518.4万 USD | 20.5万 USD | — | — | 221.9万 USD |
| 折旧和摊销 | 1041.8万 USD | 967万 USD | 951.5万 USD | 943.3万 USD | 1107万 USD |
| 营业利润 | 6791.2万 USD | 5225.6万 USD | 3671.2万 USD | 2682.9万 USD | 3642.5万 USD |
| 净利润 | 5773.4万 USD | 4403.8万 USD | 3010.5万 USD | 2063.6万 USD | 2690.7万 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化,并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR1.01亿0.10%1031.91亿 USD0.06%US$137.55+0.17%
First Trust SMID Cap Rising Dividend Achievers ETFSDVY8524.92万0.78%109.2亿 USD0.58%US$41.24+0.05%
Vanguard Morningstar Total Stock Market ETFVTI5568.32万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Guggenheim Funds Trust - Guggenheim Ultra Short Income ETFGCSH5090.08万0.22%1.46亿 USD0.25%US$49.85+0.02%
iShares Russell 2000 ETFIWM4559.03万0.06%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1955.81万0.02%954亿 USD0.05%US$235+0.80%
Guggenheim Funds Trust - Guggenheim Securitized Income ETFGISC1696.69万0.23%6790万 USD0.47%US$49.2511+0.08%
iShares Russell 2000 Growth ETFIWO1607.97万0.12%139.17亿 USD0.24%US$356.78+0.94%
iShares Core S&P Small-Cap ETFIJR
First Trust SMID Cap Rising Dividend Achievers ETFSDVY
Vanguard Morningstar Total Stock Market ETFVTI
Guggenheim Funds Trust - Guggenheim Ultra Short Income ETFGCSH
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Guggenheim Funds Trust - Guggenheim Securitized Income ETFGISC
iShares Russell 2000 Growth ETFIWOAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。